Audentes inches up after pricing $75M IPO

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $0.13 to $15.13 on its first day of trading

Read the full 172 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE